<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04596748</url>
  </required_header>
  <id_info>
    <org_study_id>ISSR-Prob-GutSkin</org_study_id>
    <nct_id>NCT04596748</nct_id>
  </id_info>
  <brief_title>Oral Probiotics on the Microbiome and Lipidome in Acne Vulgaris</brief_title>
  <official_title>Prospective Randomized Double-Blind Placebo-Controlled Study of Oral Probiotics on the Microbiome and Lipidome in Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Integrative Skin Science and Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Microbiome labs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Integrative Skin Science and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how probiotics affect sebum production and gut&#xD;
      health in those with acne vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Probiotics have been shown in previous pilot studies to be helpful in acne and this study&#xD;
      aims to examine how the gut microbiome and skin biophysical properties are shifted in those&#xD;
      with acne vulgaris. In particular, this study will assess the influence of oral spore based&#xD;
      probiotics on the skin sebum production and will assess how probiotics influence the gut&#xD;
      microbiome and the blood levels of short chain fatty acids.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind, randomized, placebo-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiota Diversity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluation of alpha diversity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Short chain fatty acids</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood acetate levels</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gut microbiome changes</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
    <description>Evaluation of alpha diversity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skin microbiome</measure>
    <time_frame>12 weeks</time_frame>
    <description>Relative abundance cutibacterium genera</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessments for GI distress</measure>
    <time_frame>4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>Self assessment using Digestive Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sebum excretion rate</measure>
    <time_frame>4 weeks, 8 weeks, 12 weeks</time_frame>
    <description>Sebumeter: 0-150 micrograms/cm^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skin hydration</measure>
    <time_frame>4,8 and 12 weeks</time_frame>
    <description>Moisturemeter: 0-150</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skin pH</measure>
    <time_frame>4,8, and 12 weeks</time_frame>
    <description>Use of pH meter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial redness - Image based</measure>
    <time_frame>4,8,12 weeks</time_frame>
    <description>BTBP Clarity Mini 3D camera</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Facial skin tone - Image based</measure>
    <time_frame>4,8,12 weeks</time_frame>
    <description>BTBP Clarity Mini 3D camera</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective assessment of the skin</measure>
    <time_frame>4,8,12 weeks</time_frame>
    <description>Self-assessment through Dermatology Quality of Life questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment of acne</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
    <description>Evaluation of acne to assess for flares</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut Microbiome Changes</measure>
    <time_frame>4, 8, 12 weeks</time_frame>
    <description>Relative abundance of Akkermansia muciniphila</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be taking a placebo supplement that they will be taking by mouth once per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be taking a probiotic supplement that they will be taking by mouth once per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Bacillus Subtilis, Bacillus Clausii, Bacillus Coagulans, Bacillus Indicus HU36, MCC 102</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo caps</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects aged 13-45&#xD;
&#xD;
          -  Subjects with acne vulgaris as diagnosed by a board-certified dermatologist,having&#xD;
             mild-moderate acne on the face with an IGA score of 2-3 and 10+ inflammatory lesions&#xD;
             on face and 15+ total lesions.&#xD;
&#xD;
          -  Subjects should experience new acne lesions on a recurrent basis within last 6 months&#xD;
&#xD;
          -  Must be willing to comply with all protocol requirements&#xD;
&#xD;
          -  Must be willing to have flash photo facial images taken with the imaging systems&#xD;
&#xD;
          -  Males must be willing to shave any facial hair&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any systemic antibiotics used to treat acne (injected or oral)within 6 months of&#xD;
             starting study. Any 14-day or shorter course of systemic antibiotics (injected or&#xD;
             oral) used to treat conditions other than acne within 1 month of starting study&#xD;
&#xD;
          -  Any topical antibiotic or benzoyl peroxide within 1 month of starting study or any&#xD;
             subject unwilling to refrain from washout of topical antibacterial or benzoyl peroxide&#xD;
             ingredient.&#xD;
&#xD;
          -  Any oral probiotic or prebiotic supplementation within past 1 month&#xD;
&#xD;
          -  Subjects must have no history of malignancy or cancer or diagnosis of gastrointestinal&#xD;
             inflammatory diseases, no history or diagnosis of epilepsy, no history or diagnosis of&#xD;
             immunologic or infectious disease (e.g. hepatitis, tuberculosis, HIV or AIDS, lupus,&#xD;
             rheumatoid arthritis)&#xD;
&#xD;
          -  Has a condition or is on medication the investigator and/or designee believe could&#xD;
             jeopardize the safety of the subject, interfere with the evaluation, or confound the&#xD;
             interpretation of the study results&#xD;
&#xD;
          -  Women who have been pregnant in the last three months, are pregnant, preparing to be&#xD;
             pregnant or lactating, or post-menopausal.&#xD;
&#xD;
          -  Is participating in a concurrent clinical research study or has participated in acne&#xD;
             or other facial study at this or any other facility in the past 4 weeks&#xD;
&#xD;
          -  Those with BMI higher than 35kg/mÂ²&#xD;
&#xD;
          -  Those that have undergone a change in hormonally based therapies, such as but not&#xD;
             limited to oral contraceptive pills or progesterone based pills within the last two&#xD;
             months. Progesterone releasing IUDs and spironolactone are considered hormone-based&#xD;
             therapy.&#xD;
&#xD;
          -  Commencement of a new diet (such as the ketogenic diet)or supplements within the 1&#xD;
             month prior to initiating participation, at the discretion of the investigator.&#xD;
&#xD;
          -  Use of medications that alter blood lipids, such as statins and anti-hyperlipidemic&#xD;
             medications&#xD;
&#xD;
          -  Is participating in or has participated in acne or other facial study at this or any&#xD;
             other facility in the past 4 weeks. Participation in survey-based studies are approved&#xD;
             at the discretion of the investigator.&#xD;
&#xD;
          -  Has a skin disease on face, other than acne, that will interfere with image collection&#xD;
             and assessment in the opinion of the investigator&#xD;
&#xD;
          -  Refusal to shave or remove facial hair that may interfere with image collection and&#xD;
             assessment.&#xD;
&#xD;
          -  Severe acne or nodulocystic acne, at the discretion of the investigator&#xD;
&#xD;
          -  Use of isotretinoin within the 6 months prior to starting in study.&#xD;
&#xD;
          -  Persons unwilling to avoid the following during the 4 weeks prior and during the&#xD;
             duration of the study: self-tanning, spa tanning, or artificial tanning.&#xD;
&#xD;
          -  Known allergy or irritation to the supplement or facial products utilized in the study&#xD;
&#xD;
          -  Current tobacco smokers, OR those that have smoked tobacco over the past year, OR a 5&#xD;
             year-pack year history of smoking tobacco&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Adults unable to consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Raja K Sivamani, MD</last_name>
    <phone>916-524-1216</phone>
    <email>raja.sivamani@integrativeskinresearch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Integrative Skin Science and Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raja K Sivamani, MD</last_name>
      <phone>916-524-1216</phone>
      <email>raja.sivamani@integrativeskinresearch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 9, 2020</study_first_submitted>
  <study_first_submitted_qc>October 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>November 20, 2020</last_update_submitted>
  <last_update_submitted_qc>November 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Integrative Skin Science and Research</investigator_affiliation>
    <investigator_full_name>Raja Sivamani</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>acne vulgaris</keyword>
  <keyword>skin</keyword>
  <keyword>dermatology</keyword>
  <keyword>acne</keyword>
  <keyword>microbiome</keyword>
  <keyword>probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

